Detalhe da pesquisa
1.
Prevalence, admission rates and hypoxia due to COVID-19 in patients with rheumatic disorders treated with targeted synthetic or biologic disease modifying antirheumatic drugs or methotrexate: a nationwide study from Iceland.
Ann Rheum Dis
; 80(5): 671-672, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33402343
2.
Long-term follow-up in lupus nephritis patients treated with rituximab--clinical and histopathological response.
Rheumatology (Oxford)
; 52(5): 847-55, 2013 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-23287364
3.
Clinical improvements in proliferative vs membranous lupus nephritis following B-cell depletion: pooled data from two cohorts.
Rheumatology (Oxford)
; 49(8): 1502-4, 2010 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-20427294
4.
Rituximab-treated membranous lupus nephritis: clinical outcome and effects on electron dense deposits.
Ann Rheum Dis
; 70(6): 1172-3, 2011 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-21367763
5.
[Equipment in Landspítali University Hospital: compassion-professionalism-safety-progress?[editorial]]. / Taekjabúnadur Landspítala: umhyggja-fagmennska-öryggi-frambróun?
Laeknabladid
; 98(9): 447, 2012 09.
Artigo
em Islandês
| MEDLINE | ID: mdl-22947625
6.
Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis.
Arthritis Rheum
; 56(4): 1263-72, 2007 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-17393458